Fagron Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Fagron's estimated annual revenue is currently $14.1M per year.(i)
  • Fagron's estimated revenue per employee is $201,000

Employee Data

  • Fagron has 70 Employees.(i)
  • Fagron grew their employee count by 1% last year.

Fagron's People

NameTitleEmail/Phone
1
VP, Sales Operations B&EReveal Email/Phone
2
Senior Director Marketing | Brands & EssentialsReveal Email/Phone
3
Quality DirectorReveal Email/Phone
4
Senior Director Professional ServicesReveal Email/Phone
5
R&D ManagerReveal Email/Phone
6
Customer Account and Pricing SpecialistReveal Email/Phone
7
Sales DirectorReveal Email/Phone
8
Information Technology Business AnalystReveal Email/Phone
9
SALES REPRESENTATIVE / ACCOUNT MANAGERReveal Email/Phone
10
Accounting ProfessionalReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$85.6M4268%N/AN/A
Add Company

What Is Fagron?

Follow us on Twitter: @FagronUS Like us on Facebook: Fagron US Follow us on Instagram: @fagron_us Fagron, Inc. - USA Fagron's strategy is focused on the optimization and innovation of pharmaceutical compounding. As an R&D scientific pharmaceutical compounding supplier, Fagron wants to widen the therapeutic scope of the prescriber to enable tailor-made pharmaceutical care. Through its activities, Fagron supports the unique selling point of the pharmacist. Fagron, Inc., is headquartered in St. Paul, Minnesota. The company has continued to grow through the years because of its innovation and ability to bring new products to the U.S. compounding market. Since 1980, Fagron, Inc. has been a US Food and Drug Administration-registered pharmaceutical supplier, adhering strictly to current Good Manufacturing Practices (cGMP). Bulk Pharmaceutical Ingredients (BPI) are purchased from reputable, registered, and validated manufacturers. Incoming BPIs are initially quarantined, then sampled and tested for identity, strength, quality, and purity in our Quality Control Laboratories, using methods as set forth in the applicable monographs of USP, NF, British Pharmacopoeia (BP), or European Pharmacopoeia (EP). Repackaging is performed in our climate-monitored facility, then retested by Quality Control (QC) and reviewed by Quality Assurance (QA) before release to the market.

keywords:N/A

N/A

Total Funding

70

Number of Employees

$14.1M

Revenue (est)

1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Fagron News

2022-04-13 - Fagron reports 16% increase in revenue to € 156.4 million

Fagron, the leading global player in pharmaceutical compounding, today publishes its quarterly results for the period ending 31 March 2022.

2022-04-06 - Fagron publishes agenda 2022 annual general meeting and ...

The Board of Directors of Fagron NV (Fagron) invites the holders of shares and subscription rights of Fagron to attend the annual general...

2022-03-22 - Fagron NV (EBR:FAGR) institutional owners may be pleased with recent gains after 14% loss over the past year

What Does The Institutional Ownership Tell Us About Fagron? Institutional investors commonly compare their own returns to the returns of a...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$22.2M700%N/A
#2
$12.7M706%N/A
#3
$11.5M71-5%N/A
#4
$15.5M713%N/A
#5
$13.4M714%N/A